Hiroshi Nakagomi1,2, Ikuko Sakamoto3, Yosuke Hirotsu4, Kenji Amemiya4, Hitoshi Mochiduki4, Masao Omata4,5. 1. Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, 400-0027, Japan. h-nakagomi@ych.pref.yamanashi.jp. 2. Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, 400-0027, Japan. h-nakagomi@ych.pref.yamanashi.jp. 3. Department of Gynecology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, 400-0027, Japan. 4. Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, 400-0027, Japan. 5. University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8654, Japan.
Abstract
BACKGROUND: PALB2 (Partner and Localizer of BRCA2) was identified as a moderate-risk gene in breast and pancreatic cancers. Recently, it was reported that PALB2 carriers have a high risk of developing breast cancer, with the cumulative risk of 34 % by the age of 70. PATIENTS AND METHODS: Peripheral blood samples from 155 patients at risk for hereditary breast and/or ovarian cancer were tested for BRCA1/2 and PALB2 by targeted sequencing using a next-generation sequencer. Of these 155, 146 met NCCN criteria and the remaining 9 did not. RESULTS: BRCA1/2 analysis was performed on 155 patients, for whom the results were reported previously (Hirotsu Y et al. Mol Genet Genomic Med, doi:10.1002/mgg3.157, 2015). Eleven patients were identified to have deleterious BRCA mutations (Hirotsu Y et al. Mol Genet Genomic Med, doi:10.1002/mgg3.157, 2015). However, none of the 155 patients were found to have deleterious PALB2 germline mutations. Missense mutations [variants of uncertain significance (VUS)] of PALB2 were found in 12 cases. In silico analyses by SIFT (Sorting Intolerant Form Tolerant) and PolyPhen2 (Polymorphism Phenotyping version 2) indicated that 2 of 12 VUS were deleterious and probably damaging. CONCLUSIONS: This is the first report on PALB2 mutations in Japan, revealing two missense mutations as "deleterious and probably damaging" by in silico analyses, but no PALB2 premature truncation mutations were identified. The sample size is relatively small and a larger cohort study is needed in Japan.
BACKGROUND:PALB2 (Partner and Localizer of BRCA2) was identified as a moderate-risk gene in breast and pancreatic cancers. Recently, it was reported that PALB2 carriers have a high risk of developing breast cancer, with the cumulative risk of 34 % by the age of 70. PATIENTS AND METHODS: Peripheral blood samples from 155 patients at risk for hereditary breast and/or ovarian cancer were tested for BRCA1/2 and PALB2 by targeted sequencing using a next-generation sequencer. Of these 155, 146 met NCCN criteria and the remaining 9 did not. RESULTS:BRCA1/2 analysis was performed on 155 patients, for whom the results were reported previously (Hirotsu Y et al. Mol Genet Genomic Med, doi:10.1002/mgg3.157, 2015). Eleven patients were identified to have deleterious BRCA mutations (Hirotsu Y et al. Mol Genet Genomic Med, doi:10.1002/mgg3.157, 2015). However, none of the 155 patients were found to have deleterious PALB2 germline mutations. Missense mutations [variants of uncertain significance (VUS)] of PALB2 were found in 12 cases. In silico analyses by SIFT (Sorting Intolerant Form Tolerant) and PolyPhen2 (Polymorphism Phenotyping version 2) indicated that 2 of 12 VUS were deleterious and probably damaging. CONCLUSIONS: This is the first report on PALB2 mutations in Japan, revealing two missense mutations as "deleterious and probably damaging" by in silico analyses, but no PALB2 premature truncation mutations were identified. The sample size is relatively small and a larger cohort study is needed in Japan.
Entities:
Keywords:
Breast cancer; Japanese; Ovarian cancer; PALB2 mutation
Authors: Jin Ho Kim; Doo Ho Choi; Dae Yeon Cho; Sei Hyun Ahn; Byung Ho Son; Bruce G Haffty Journal: Breast Cancer Res Treat Date: 2010-03-06 Impact factor: 4.872
Authors: Hannele Erkko; Bing Xia; Jenni Nikkilä; Johanna Schleutker; Kirsi Syrjäkoski; Arto Mannermaa; Anne Kallioniemi; Katri Pylkäs; Sanna-Maria Karppinen; Katrin Rapakko; Alexander Miron; Qing Sheng; Guilan Li; Henna Mattila; Daphne W Bell; Daniel A Haber; Mervi Grip; Mervi Reiman; Arja Jukkola-Vuorinen; Aki Mustonen; Juha Kere; Lauri A Aaltonen; Veli-Matti Kosma; Vesa Kataja; Ylermi Soini; Ronny I Drapkin; David M Livingston; Robert Winqvist Journal: Nature Date: 2007-02-07 Impact factor: 49.962
Authors: Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton Journal: Nat Genet Date: 2006-12-31 Impact factor: 38.330
Authors: Natalia Bogdanova; Anna P Sokolenko; Aglaya G Iyevleva; Svetlana N Abysheva; Magda Blaut; Michael Bremer; Hans Christiansen; Margret Rave-Fränk; Thilo Dörk; Evgeny N Imyanitov Journal: Breast Cancer Res Treat Date: 2010-12-17 Impact factor: 4.872
Authors: Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean Journal: Nature Date: 2012-11-01 Impact factor: 49.962
Authors: Ana Blanco; Miguel de la Hoya; Ana Osorio; Orland Diez; María Dolores Miramar; Mar Infante; Cristina Martinez-Bouzas; Asunción Torres; Adriana Lasa; Gemma Llort; Joan Brunet; Begoña Graña; Pedro Perez Segura; María José Garcia; Sara Gutiérrez-Enríquez; Ángel Carracedo; María-Isabel Tejada; Eladio A Velasco; María-Teresa Calvo; Judith Balmaña; Javier Benitez; Trinidad Caldés; Ana Vega Journal: PLoS One Date: 2013-07-23 Impact factor: 3.240
Authors: Joanne Kotsopoulos; Victoria Sopik; Barry Rosen; Isabel Fan; John R McLaughlin; Harvey Risch; Ping Sun; Steven A Narod; Mohammad R Akbari Journal: Fam Cancer Date: 2017-01 Impact factor: 2.375
Authors: Thales C Nepomuceno; Giuliana De Gregoriis; Francisco M Bastos de Oliveira; Guilherme Suarez-Kurtz; Alvaro N Monteiro; Marcelo A Carvalho Journal: Int J Mol Sci Date: 2017-08-31 Impact factor: 5.923